Salute e Benessere

Cell Based Assay Market Poised for Significant Growth, projected to Reach USD…

Download PDF Brochure: https://www.marketresearchintellect.com/download-sample/?rid=201801 Download PDF Brochure: https://www.marketresearchintellect.com/download-sample/?rid=201801 202 - Pages 126 – Tables 37 – Figures Scope Of The Report Cell Based Assay Market Overview Market Definition and Scope The Cell Based Assay Market refers to the segment of the pharmaceutical and biotechnology industries focused on testing cellular responses to various compounds,...
PR Newswire
15/10/2024

Cellular Health Screening & Health Testing Market Poised for Remarkable Growth…

Download PDF Brochure: https://www.marketresearchintellect.com/download-sample/?rid=1014477 Download PDF Brochure: https://www.marketresearchintellect.com/download-sample/?rid=1014477 202 - Pages 126 – Tables 37 – Figures Scope Of The Report Cellular Health Screening & Health Testing Market Overview Market Growth and Projections The Cellular Health Screening & Health Testing Market is experiencing rapid growth, driven by increasing consumer awareness...
PR Newswire
15/10/2024

Neurogenomics Market to Reach $4.68 Billion by 2031--Exclusive Report by…

Download FREE PDF Brochure Of Neurogenomics Market - Download FREE PDF Brochure Of Neurogenomics Market - https://www.meticulousresearch.com/download-sample-report/cp_id=6019 Neurogenomics is a multidisciplinary field that integrates genome sciences and neurobiology. It examines the genome's impact on the structure, evolution, development, and functionality of the nervous system. This research encompasses genetic analyses, including the assessment of genome sequencing outputs like...
PR Newswire
15/10/2024

Body Contouring Devices Market to Hit USD 3.00 Billion by 2029 with 11.4% CAGR |…

Browse in-depth TOC on "Body Contouring Devices Market" Browse in-depth TOC on "Body Contouring Devices Market" 349 - Tables 44 - Figures 309 - Pages By product, the body contouring devices market is segmented into non-invasive and invasive devices. In 2023, the non-invasive devices segment held the majority share in the body contouring devices market. The largest portion of non-invasive segment is driven by added benefits offered by the non-invasive device, predominantly...
PR Newswire
15/10/2024

Monument Therapeutics Secures £1M Investment to Fund Its Schizophrenia Programme…

Dr Randeep Grewal, who has served as a board observer at Monument representing angel investors since 2022, has been appointed as board Chair. Randeep brings extensive experience from his other roles as Chair of Bellevue Healthcare Trust and non-executive director of organisations including Hox Therapeutics, the Global Smaller Companies Trust and the Monks Investment Trust. Furthermore, his previous background as a fund manager and a vascular surgeon provides a unique blend of financial and…
PR Newswire
15/10/2024

Accure Acne Announces New FDA Clearance for the Long-Term Treatment of Acne

"This achievement cannot be overstated," commented Christopher Carlton, Accure Acne, Inc.'s Co-Founder, Chairman of the Board and Chief Executive Officer. "After many years of rigorous technical, scientific, and clinical development, The Accure Laser has delivered yet another milestone achievement-the ability to provide a significant, sustained, and durable drug-free alternative for acne patients and their providers," continued Mr. Carlton. "This is the vision of Accure…
PR Newswire
15/10/2024

KFNCCC A Regional Leader in Pediatric Cancer Treatment

RIYADH, Saudi Arabia, Oct.15, 2024(GLOBE NEWSWIRE) -- At the heart of advanced medical efforts in pediatric oncology in the Kingdom, King Fahad National Centre for Children's Cancer (KFNCCC), affiliated with King Faisal Specialist Hospital & Research Centre (KFSHRC), stands as a unique healthcare institution in Saudi Arabia and the Middle East. Since its founding in 1997, the center has become a beacon of hope and medical innovation, operating within a comprehensive therapeutic...
Nasdaq GlobeNewswire
15/10/2024

Operation Smile Featured in "Beyond the Code," a New Branded Series that…

"We are proud to be part of Beyond the Code," said Dr. Billy Magee, Chief Medical Officer, Operation Smile. "The story produced for Operation Smile highlights our pioneering use of AI technology to enhance healthcare delivery. By integrating AI into our planning and evaluation processes, we are not only raising the standard of care but also building local capacity, bringing life-changing surgical care closer to the communities we serve." "We are proud to be part of…
PR Newswire
15/10/2024

Cytosurge and Lexogen Partner to Advance Live-Cell Sequencing

Collaboration to Enable Sequencing of Cellular Biopsies Cytosurge's FluidFM ®OMNIUM platformwithLexogen's LUTHOR HDkit to offer a streamlined workflow that preserves cell viability, making live-cell sequencing more accessible and scalable for researchers. For more details,download the shared application note. Live-seq is a groundbreaking technology developed at ETH Zurich and EPFL, Switzerland, that allows the sequencing of a cell's transcriptome while keeping the cell alive...
Nasdaq GlobeNewswire
15/10/2024

Cytosurge and Lexogen Partner to Advance Live-Cell Sequencing

Live-seq is a groundbreaking technology developed at ETH Zurich and EPFL, Switzerland, that allows the sequencing of a cell's transcriptome while keeping the cell alive. This represents a paradigm shift from traditional methods that kill cells during sampling, providing new opportunities for dynamic, time-resolved transcriptomic studies. Cytosurge's FluidFM® technology enables gentle extraction of cytoplasmic biopsies without harming the cell. Extremely low amounts of RNA (typically <1 pg) in…
PR Newswire
15/10/2024

Major shareholder announcement

Pursuant to Section 30 of the Danish Capital Markets Act, Novonesis hereby announces that BlackRock, Inc. has notified Novonesis of the following status relating to the position of share capital attached to shares and share capital through financial instruments.Per October 11, 2024, BlackRock, Inc. has adjusted its holding of shares to an equivalent of 23,045,290 shares, corresponding to 4.92% (previously 4.95%) of the total share capital attached to shares. The combined total of share...
Nasdaq GlobeNewswire
15/10/2024

Akari Therapeutics Announces Effectiveness of Form S-4 and General Meeting Date…

BOSTON and LONDON, Oct.15, 2024(GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), an innovative biotechnology company developing advanced therapies for autoimmune and inflammatory diseases, announces the effectiveness of the Form S-4, originally filed with the SEC on September 13, 2024 related to the merger of Akari Therapeutics, Plc (the Company) and Peak Bio, Inc. The Form S-4 was declared effective by the SEC on October 11, 2024 allowing the Company to definitively schedule the...
Nasdaq GlobeNewswire
15/10/2024

Gan & Lee Pharmaceuticals' Three Innovative Drugs: GZR18 Injection, GZR4…

GZR18 Injection: a Phase 2 Study evaluate the Efficacy and Safety of GZR18 Injective vs. Semaglutide (Ozempic®) in Chinese Patients with Type 2 DiabetesThe Phase 2b clinical trial (CTR20232069) is a multicenter, randomized, open-label study comparing the efficacy and safety of GZR18 injection versus semaglutide (Ozempic®) in Chinese adult T2D patients with poor glycemic control on lifestyle interventions and/or unregulated use of anti-diabetic drugs, and on oral anti-diabetic treatment for at…
PR Newswire
15/10/2024

Epitomee Medical to Present the Epitomee Breakthrough Oral Delivery Platform at…

Epitomee's presentation will cover the following topics: Epitomee's presentation will cover the following topics: The PODD Conference, in its 14th year, brings together over 800+ delegates from pharma, biotech, drug delivery, investors and academia. The event fosters collaboration across industries, to develop more effective therapies, improve the patient experience and extend the lifecycle of medicines. PODD features innovative technologies to enhance the delivery of various drug types,...
PR Newswire
15/10/2024

uniQure Announces Dosing of First Patient in Phase I/II Clinical Trial of…

uniQureN.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced that the first patient has been dosed in the Phase I/II clinical trial of AMT-162 for the treatment of amyotrophic lateral sclerosis (ALS) caused by mutations in superoxide dismutase 1 (SOD1), a rare, inherited and progressive motor neuron disease. EPISOD1 is a Phase I/II multi-center, open-label trial being conducted in the United States with...
Nasdaq GlobeNewswire
15/10/2024

Lutris Pharma Completes Enrollment in Phase 2 Trial of LUT014 for the Treatment…

The phase 2, randomized, double-blind, placebo-controlled trial has enrolled a total of 117 subjects at 20 international sites, including Memorial Sloan Kettering Cancer Center, MD Anderson Cancer Center and Dana Farber Cancer Institute. The trial is evaluating the efficacy and safety of two strengths of LUT014 gel, 0.03% or 0.10%, applied once daily for 4 weeks, compared to placebo (with a randomization of 1:1:1), in patients with mCRC who develop Grade 2 or non-infected Grade 3 EGFR…
PR Newswire
15/10/2024

New research reveals hidden cybercrime mental health crisis

A survey of 1,002 Britons who have been a victim of cybercrime in the past year, commissioned by Akamai, reveals most are ashamed of their experience, feel they've done something wrong, and believe there's an unfair stigma placed on them. A survey of 1,002 Britons who have been a victim of cybercrime in the past year, commissioned by Akamai, reveals most are ashamed of their experience, feel they've done something wrong, and believe there's an unfair stigma placed on them. Cybercrime causes...
PR Newswire
15/10/2024

Junshi Biosciences Announces Toripalimab Obtained Approval for Marketing in…

®, Hong Kong trade name: LOQTORZI ® ) has been approved for marketing in India and China's Hong Kong Special Administrative Region (“SAR”), for treatment of recurrent or metastatic nasopharyngeal carcinoma (“NPC”). The approved indications are: 1) toripalimab in combination with cisplatin and gemcitabine, for first line treatment of adults with metastatic or with recurrent, locally advanced NPC; 2) toripalimab as a single agent, for the treatment of adults with recurrent unresectable or...
Nasdaq GlobeNewswire
15/10/2024

WARBURG PINCUS STRENGTHENS ITS EUROPEAN BUSINESS AND GLOBAL HEALTHCARE GROUP…

The senior adviser appointments follow the recent announcement of Enovo Life Sciences, a new life sciences platform institutionally capitalized by funds advised by Warburg Pincus and led by life sciences industry veterans, Mario Philips and Roel Gordijn. These announcements demonstrate the continued momentum in Warburg Pincus's European business. Jake Strauss, a Managing Director in the global healthcare group, was recently announced as head of the firm's European healthcare efforts and Tobias…
PR Newswire
15/10/2024

Genmab Announces Net Sales of DARZALEX® (daratumumab) for Third Quarter of 2024

Company Announcement Net sales of DARZALEX ®in the third quarter of 2024 totaled USD 3,016 millionGenmab receives royalties on worldwide net sales from Janssen Biotech, Inc. (Janssen) COPENHAGEN, Denmark; October 15, 2024 – Genmab A/S (Nasdaq: GMAB) announced today that worldwide net trade sales of DARZALEX ®(daratumumab), including sales of the subcutaneous (SC) product (daratumumab and hyaluronidase-fihj , sold under the tradename DARZALEXFASPRO® ...
Nasdaq GlobeNewswire
15/10/2024

Alimentiv and Satisfai Health Extend Partnership to Accelerate Development of…

"AI-powered standardization of disease scoring provides unprecedented insights, transforming data analysis and ultimately leading to better treatment outcomes for patients in clinical trials. As the leader in the field, Alimentiv will continue to lead this space and invest in innovative imaging solutions to provide more accurate analyses, highly competitive trial costs, and support sponsors with faster timelines," said Pierre Gaudreault, CEO, Alimentiv. "AI-powered standardization…
PR Newswire
15/10/2024

Boehringer Ingelheim and WHO Foundation join forces to promote equitable access…

Boehringer Ingelheim, a biopharmaceutical company active in both human and animal health, in partnership with WHO Foundation, today pledged USD 5 million to advance access to quality healthcare services for all, with a special focus on vulnerable populations in the Americas who are at greater risk of suicide.Through this partnership with the WHO Foundation, Boehringer Ingelheim will provide financial support to WHO's Fourteenth General Program of Work, spanning from 2025 to 2028,...
Nasdaq GlobeNewswire
15/10/2024

AuriGen Medical Pioneers Next-Generation Atrial Fibrillation Technology with…

Atrial fibrillation ("AF") affects over 60 million people worldwide and significantly increases stroke risk, with over 90% of stroke-causing clots originating in the left atrial appendage ("LAA"). This makes LAA closure vital for patients who cannot tolerate long-term anticoagulation therapy. The Zenith device simplifies LAA closure, crucial for reducing stroke risk in AF patients. Atrial fibrillation ("AF") affects over 60 million people worldwide and significantly…
PR Newswire
15/10/2024

Commit Biologics appoints Mikkel Wandahl Pedersen as Chief Scientific Officer

Prior to Nykode, Dr Pedersen served as CSO of Symphogen (Ballerup, Denmark), where he held broad R&D responsibilities for the antibody discovery platform, lead discovery, pre-clinical as well as translational pharmacology, and advanced a number of products through IND studies and into the clinic. Following the acquisition of Symphogen by Servier, he played a critical role in the integration of the R&D team. Prior to Nykode, Dr Pedersen served as CSO of Symphogen (Ballerup,Denmark )…
PR Newswire
15/10/2024
Altri  Comunicati